Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Bryan Sequeira
Anne Wojcicki Had a Fully Financed Plan to Take 23andMe Private. Then It Fell Apart.
23andMe CEO Anne Wojcicki has been trying to take the DNA testing company private this past year, making clear along the way that she would oppose any deal to sell the business to someone else. Wojcicki later softened her opposition, but that didn’t stop her from trying to buy the company she co-founded. A flurry of new proposals from Wojcicki over the past month failed to win over the company’s board of directors. Now 23andMe is preparing to sell its assets under bankruptcy protection.
6 Things to Know About Trump’s New CDC Director Pick
On Monday, President Donald Trump selected Susan Monarez — the current acting director of the Centers for Disease Control and Prevention — to lead the agency going forward. Below are six things to know about this nomination. This nomination replaces one that the White House withdrew on March 13. Trump had initially chosen physician and former Republican congressman Dave Weldon to lead the CDC.
PBGH Offers Advisory Services to Support Employers’ Fiduciary Responsibilities
The Purchaser Business Group on Health (PBGH) is expanding its advisory services to all large employers to help them meet their fiduciary responsibilities, the organization announced last week. PBGH is a nonprofit representing 40 private employers and public entities in the U.S. These advisory services were previously only available to PBGH’s members.
Novo Nordisk Bets $200M on Triple-Targeting Drug for Obesity and Other Metabolic Diseases
Novo Nordisk is expanding its prospects in obesity and other metabolic disorders by securing rights to an early-clinical engineered peptide whose effects comes from activating three receptors — the same three targets hit by a next-generation weight drug in development by rival Eli Lilly. According to deal terms announced Monday, Novo Nordisk is paying United Biotechnology $200 million up front for global rights to its drug, UBT251.
How Are Hospitals Faring Financially in 2025?
Kaufman Hall recently released its first report analyzing hospitals’ financial data from 2025, and the advisory firm found that hospitals kicked off this year with a stable performance. The report examined more than 1,300 hospitals’ financial data from January. Hospitals’ monthly median operating margin was 4.4% in January, up from 3.7% the month before — and much higher than the 2.1% recorded for 2024 as a whole.
Aledade, Humana Expand Value-Based Partnership to Support FQHCs and Rural Health Clinics
Aledade and Humana have expanded their value-based care partnership to support rural health clinics and Federally Qualified Health Centers (FQHCs), they announced on Thursday. Bethesda, Maryland-based Aledade helps independent practices, health centers and clinics engage in value-based care through data insights, policy expertise and contracting support.
Evolving Capacity to Meet Advanced Biologics Therapies
The use of biologics is rapidly increasing as new drugs are approved for label expansions. Monoclonal antibodies, multispecific antibodies, and antibody-drug conjugates (ADCs) are being implemented in an array of fields, including oncology, immunology, and neurology. As clinical demand for biologics increases, biopharmaceutical companies must ensure that they have the manufacturing capacity available to produce enough biologics.
FarmboxRx Introduces Platform for Addressing SDOH Needs
FarmboxRx, a healthy food company, has launched a social needs solutions platform that aims to address health gaps for health plan members, the company announced Tuesday. Boston-based FarmboxRx contracts with payers (primarily Medicaid and Medicare programs) to deliver produce boxes, cooking kits, educational materials and pantry items to patients’ doors.
Sanofi Expands Immunology Prospects, Acquiring Novel Bispecific Drug in $600M Deal
Bispecific antibodies first reached patients as cancer treatments, but a growing number of companies are working to expand these therapies to autoimmune diseases. Sanofi is adding a new contender, agreeing to pay $600 million for a bispecific drug with an approach that could be first in class. The sum announced Thursday is an upfront payment for Dren Bio’s drug candidate, DR-0201.
Evvy Launches Fertility Insights Offering Via Vaginal Microbiome Test
Evvy, a women’s health company, is now offering fertility insights through its vaginal microbiome test, the company announced on Tuesday. New York City-based Evvy is a direct-to-consumer company. Its vaginal microbiome test, starting at $129, checks for bacteria and fungi (or microbes) in people’s vaginas. After taking the test, people receive a report that explains the microbes found in the vagina and the health conditions related to those microbes.
Why Providers Are Stalling When It Comes to Scaling AI
Hospitals are poised to spend billions on AI in the coming years, but many remain ill-prepared to gauge the true return they are getting from these investments. Health system leaders say they are still figuring this process out and experimenting with different ways to measure AI’s effectiveness — ranging from hard metrics like patient outcomes to softer indicators like physician job satisfaction.
Wall Street is Profiting From America’s Autism Crisis - MedCity News
Mary H. is a mother of three boys living with her family in Georgia. Her middle son, Jack, was diagnosed with autism at age three. Despite getting Jack into an early intervention program, the wait list for behavior therapy — as for most families in Georgia and across the country — stretched to more than a year. With his behavior impeding his speech and occupational therapy, the family had run out of options.
Prioritizing AI in the C-Suite: Why Every Hospital Needs a CAIO
Sandy Gupta is the Chief Operating Officer and co founder at Innovaccer, a leading San Francisco-based healthcare IT company dedicated to accelerating innovation in healthcare.
Liver Failure-Associated Death Reported in Patient Treated With Sarepta Gene Therapy Elevidys
A patient has died following treatment with Elevidys, the Sarepta Therapeutics product that is the only FDA-approved gene therapy for Duchenne muscular dystrophy, the company disclosed Tuesday. The patient, a young man, suffered acute liver failure after receiving the therapy, Sarepta said. Liver injury is a known complication risk of Elevidys and other gene therapies that use an adeno-associated (AAV) virus to deliver the one-time treatment to cells.
Modernizing Fax Systems in Healthcare: A Reliable Foundation for Interoperability
Healthcare providers are under immense pressure to deliver high-quality care while managing financial constraints, operational inefficiencies, and an ever-evolving regulatory landscape. Vital to overcoming these challenges is the need for seamless communication and data exchange across systems. Fewer than one in three hospitals can electronically find, send, receive, and integrate patient information from another provider, indicating ongoing challenges in achieving full interoperability.
How the American Cancer Society Is Using LLMs to Accelerate Research
The American Cancer Society is betting on generative AI’s potential to accelerate cancer research, having struck a multi-year collaboration with Layer Health this month. Boston-based Layer, founded in 2023, is a healthcare AI company that uses large language models (LLMs) to improve data abstraction and draw insights from EHR data. Working together, the partners will abstract data from thousands of medical charts of patients enrolled in the American Cancer Society’s research studies.
AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition
AstraZeneca already has cell therapies in its pipeline, and it is now expanding its scope further with a deal to acquire EsoBiotec, a company in early clinical development with therapies made by engineering immune cells inside a patient’s body. Under acquisition terms announced Monday, AstraZeneca will pay $425 million up front for all outstanding equity of privately held EsoBiotec.
Fluency Isn’t Intelligence in Healthcare
As two people who have spent careers at the intersection of healthcare delivery and innovation, we have both watched the AI revolution unfold with both excitement and concern. While artificial intelligence promises to transform healthcare, however, we must separate reality from hype to harness its true potential. Let’s be clear: AI in healthcare didn’t start with ChatGPT. For decades, healthcare organizations have been using machine learning and pattern recognition to assist medical professionals.
How Are Telehealth CEOs Reacting to Congress’ Latest Spending Legislation?
Congress passed a continuing resolution last week to fund the federal government through September 30 and avoid a government shutdown. The legislation extended some key healthcare provisions, letting them live on for another six months. The resolution extends the enhanced low-volume adjustment program and the Medicare-dependent hospital program, extends add-on payments for ambulance services, and eliminates the Medicaid disproportionate share hospital cuts through the next six months.
Gene Therapy Biotech MeiraGTx Strikes Deal Bringing Generative AI to Pivotal Parkinson’s Trial
MeiraGTx has one gene therapy in a potentially pivotal clinical trial for cancer patients and another gene therapy ready to start Phase 3 in Parkinson’s disease. Completing the studies will be expensive and raising money is challenging with stock market volatility increasing by the day. MeiraGTx found another way to fund both studies.
Why Your Patients Are Leaving and How to Stop It
Patient loyalty has never been more fragile. With numerous healthcare choices available, patients expect personalized experiences, clear communication, and easy access to care. When those expectations aren’t met, they look elsewhere—leading to patient churn, missed revenue opportunities, and fragmented care. At the core of this challenge is patient engagement. It’s not just about communication; it’s about building trust, supporting adherence, and ultimately influencing health outcomes.
Novo Nordisk Launches Lower-Cost Wegovy, Following Eli Lilly Into Direct-to-Patient Sales
Novo Nordisk is expanding its reach in the obesity medicines market by making its blockbuster weight loss drug Wegovy available directly to certain patients for more than half off the product’s list price. The new offering announced Wednesday is open to uninsured patients who pay for their medicines in cash as well as those whose insurance does not cover obesity drugs. Patients will still need a prescription for the once-weekly injectable drug.
The New Reality of Hospital-Payer Contracts: How Baptist Health Negotiated with Florida Blue
Healthcare providers and insurers have long had a tense, often adversarial relationship — and the contract negotiation process between these two players has grown more complex than ever before, according to one health system CEO. Michael Mayo — CEO of Jacksonville, Florida-based Baptist Health — spoke about how his health system navigated a recent protracted negotiation with Florida Blue during an interview last week at the ViVE conference in Nashville.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Bryan
Contact Bryan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack